posted on 2023-07-21, 03:47authored byM Gros, E Segura, DC Rookhuizen, B Baudon, S Heurtebise-Chrétien, N Burgdorf, M Maurin, EA Kapp, Richard SimpsonRichard Simpson, P Kozik, JA Villadangos, MJM Bertrand, M Burbage, S Amigorena
Despite its crucial role in initiation of cytotoxic immune responses, the molecular pathways underlying antigen cross-presentation remain incompletely understood. The mechanism of antigen exit from endocytic compartments into the cytosol is a long-standing matter of controversy, confronting two main models: transfer through specific channels/transporters or rupture of endocytic membranes and leakage of luminal content. By monitoring the occurrence of intracellular damage in conventional dendritic cells (cDCs), we show that cross-presenting cDC1s display more frequent endomembrane injuries and increased recruitment of endosomal sorting complex required for transport (ESCRT)-III, the main repair system for intracellular membranes, relative to cDC2s. Silencing of CHMP2a or CHMP4b, two effector subunits of ESCRT-III, enhances cytosolic antigen export and cross-presentation. This phenotype is partially reversed by chemical inhibition of RIPK3, suggesting that endocytic damage is related to basal activation of the necroptosis pathway. Membrane repair therefore proves crucial in containing antigen export to the cytosol and cross-presentation in cDCs.
Funding
M.G. is supported by a Fondation pour la Recherche Me´ dicale grant (FDT201805005336). S.A. received funding from INSERM, Institut Curie, la Ligue contre le Cancer (Equipe Labellise´ e Ligue, EL2014.LNCC/SA), Association de Recherche contre le Cancer (ARC), the European Research Council (2013-AdG 340046 DCBIOX), ANR-10-IDEX-0001-02 PSL*, and ANR-11-LABX-0043. M.B. was supported by an ARC postdoctoral fellowship. E.S. was supported by Marie Curie Actions from the European Commission (project 39408). Research in the group of M.J.M.B. is financially supported by the Vlaams Instituut voor Biotechnologie (VIB), Ghent University, and grants from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO) (G035320N, G044518N, G0G6618N, and G0I5722N) and from the Flemish Government to Peter Vandenabeele (Methusalem BOF09/01M00709 and BOF16/MET_V/007). J.A.V. received funding from the National Health and Medical Research Council of Australia. P.K. was supported by the Wellcome Trust (101578/Z/13/Z) and Medical Research Council (MC_UP_1201/26).